Britain and America have established a major commercial pact that will maintain zero levies on British pharmaceutical shipments entering the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to boost funding on drugs through the public health system. This pledge ensures that tariffs on these vital products will be held at nothing for a period of three years.
This deal is in response to previous threats to hike import taxes on branded drug products, with potential rates discussed up to 100%.
"This deal with the United Kingdom reinforces the international landscape for new treatments and establishes long-overdue balance to American-British pharmaceutical trade," a statement noted.
Commercial Significance
Pharmaceuticals are one of the the United Kingdom's most significant goods shipped to the United States, which is by far the largest buyer for leading UK drugmakers.
Statistics reveal that in the 12 months prior to the third quarter, the UK shipped drugs totaling £11.1bn to the US. This value accounted for nearly one-fifth of all goods exports in that period.
"This deal protects work, boosts investment and facilitates the UK to establish itself as a worldwide center for medical research," a minister commented.
Key British Pledges
The agreement includes several specific changes from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it deems new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to increase total public funding on drugs from 0.3% of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage manufacturers must return to the NHS to prevent overspending will be capped at 15%. In the past, repayments were more than twenty percent.
Recent Tensions
The pact comes amid a ongoing dispute between the drug companies and the UK government over spending levels and NHS adoption.
The disagreement were exacerbated by arguments that American consumers were charged a premium for the same drugs than people in the other developed nations.
Recently, several large manufacturing plans in the UK have been paused or cancelled, while substantial expansions have been directed toward US facilities.
One official acknowledged that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the previous ten-year period.
